| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6efd738eb26ec31890b9e53e345c622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate |
2016-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96d4129995e0b5d3dc32a50c3feb526f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca1f764a886fe9ac4b150643b97142d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9007a2216d22589bf9ed88d9a10f6286 |
| publicationDate |
2016-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016161196-A1 |
| titleOfInvention |
Microrna-34 immunotherapy |
| abstract |
A method of treating a PD-L1 expressing cancer in an individual in need thereof by administering a synthetic miR-34 oligonucleotide or a combination of a synthetic miR-34 oligonucleotide and a PD-L1 or PD-1 inhibitor. A method of treating a chronic infectious disease in an individual in need thereof by administering a synthetic miR-34 oligonucleotide and a PD-L1 or PD-1 inhibitor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4035659-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11453681-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107699565-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019232160-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019180153-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11071730-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11642378-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019100618-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10517899-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10751373-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11203591-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107699565-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019060708-A1 |
| priorityDate |
2015-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |